Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: Role of TGFβ signaling pathway

Molecular Carcinogenesis

Volumn 50, Issue 7, 2011, Pages 516-527

  Walsh, Stephanie B ^a   Xu, Jianmin ^a   Xu, Hui ^a   Kurundkar, Ashish R ^b   Maheshwari, Akhil ^b   Grizzle, William E ^c   Timares, Laura ^a   Huang, Conway C ^a   Kopelovich, Levy ^d   Elmets, Craig A ^a   Athar, Mohammad ^a,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham and Children's Hospital   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Carcinogenesis; Cyclosporine a; EMT; Immune suppression; Nuclear factor of activated t cells; Skin carcinogenesis; TGF ; Tumor progression

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLOSPORIN A; FIBRONECTIN; GELATINASE A; GELATINASE B; NERVE CELL ADHESION MOLECULE; PROTEIN BAX; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CYCLOSPORINE; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; GASTROPODA; MURINAE; MUS; MUS MUSCULUS;

EID: 79958241164     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20744     Document Type: Article

References (33)

1. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007; 4: 462-469.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients - where do we stand today? Am J Transplant 2008; 8: 2192-2198.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
5. Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53: 783-790.
6. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17 (quiz 8-20).
7. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008; 8: 2205-2211.
8. Phan TA, Halliday GM, Barnetson RS, Damian DL. Spectral and dose dependence of ultraviolet radiation-induced immunosuppression. Front Biosci 2006; 11: 394-411.
9. Bach JF. The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases. Transplant Proc 1999; 31: 16S-18S.
10. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-628.
11. Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transpl Int 2006; 19: 908-914.
12. McCaffrey PG, Luo C, Kerppola TK, et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993; 262: 750-754.
13. Walter DH, Haendeler J, Galle J, Zeiher AM, Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation 1998; 98: 1153-1157.
14. Tang X, Zhu Y, Han L, et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 2007; 117: 3753-3764.
15. Iwamura H, Sato M, Wakitani K., Comparative study of glucocorticoids, cyclosporine A, and JTE-607 [(-)-Ethyl-N[3, 5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]be nzoyl]-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Ther 2004; 311: 1256-1263.
16. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
17. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-2810.
18. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
19. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
20. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19: 156-172.
21. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004; 66: 383-389.
22. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874.
23. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
24. Basu A, Contreras AG, Datta D, et al. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res 2008; 68: 5689-5698.
25. Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 2008; 132: 299-310.
26. Kahl CR, Means AR. Calcineurin regulates cyclin D1 accumulation in growth-stimulated fibroblasts. Mol Biol Cell 2004; 15: 1833-1842.
27. Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol 2003; 284: C1593-C1603.
28. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-1025.
29. Athar M, Kim AL, Ahmad N, Mukhtar H, Gautier J, Bickers DR. Mechanism of ultraviolet B-induced cell cycle arrest in G2/M phase in immortalized skin keratinocytes with defective p53. Biochem Biophys Res Commun 2000; 277: 107-111.
30. Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69: 2230-2231.
31. Waiser J, Dell K, Bohler T, et al. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. Nephrol Dial Transplant 2002; 17: 1568-1577.
32. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005; 20: 2215-2225.
33. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol 2005; 167: 395-407.